A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer Clinical Trial

Official title:

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Pancreatic Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05657418
• Other study ID #: JS107-002-I
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 30, 2022
• Est. completion date: December 30, 2024

Study information

• Verified date: October 2022
• Source: Shanghai Junshi Bioscience Co., Ltd.
• Contact: Xiaohong Ding, PM
• Phone: 86 021-61058800
• Email: xiaohong_ding[@]junshipharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 106
• Est. completion date: December 30, 2024
• Est. primary completion date: September 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form;

2. Aged =18 years and =75 years when the subject signed the informed consent;

3. Locally advanced unresectable or metastatic malignant solid tumors diagnosed histologically ;

4. Provide past tumor samples or fresh tumor tissue biopsy samples;

5. The physical status score is 0 or 1 on the Eastern Oncology Collaboration (ECOG) scale;

6. The expected survival is =3 months;

7. There should be at least one measurable lesion according to RECIST V1.1 evaluation criteria;

8. Any adverse events and/or complications resulting from prior treatment, including surgery or radiation therapy, that have been adequately resolved to level 0 or 1 (according to the NATIONAL Cancer Institute Standard for General Terminology of Adverse Events (NCI-CTCAE 5.0) or to the level specified in the inclusion criteria; Any grade of hair loss/pigmentation and other long-term toxicity caused by treatment, except those that are irreversible and do not affect study dosing/compliance and patient safety at the discretion of the investigator;

9. Good organ function;

10. Within 7 days prior to the first dose, women of reproductive age must be confirmed as having a negative serum pregnancy test and consent to use effective contraception during the duration of study drug use and for 6 months after the last dose. Male patients with a female partner of reproductive age agreed to use effective contraception during the study drug use period and for 6 months after the last dose.

Exclusion Criteria:

1. Prior treatment with drugs or other therapies targeting CLDN18.2;

2. A history of severe allergic reactions to to any component of JS107;

3. Received radiotherapy (except palliative radiotherapy for symptom control), chemotherapy, targeted therapy, endocrine therapy and other antitumor therapies, or other investigational drugs within 4 weeks before the administration of the first dose;

4. Received any monoclonal antibody or antibody conjugate within 4 weeks prior to administration of the first study drug or within 5 half-lives (depend on whichever is shorter);

5. Serious infection (CTCAE> grade 2) occurred within 14 days before the first dose;

6. Patients with other malignant tumors except for the tumor treated in the study within 5 years prior to the administration of the first study drug (exceptions included: cured malignancies that had not recurred within 3 years prior to study enrollment; Completely resected basal and squamous cell skin cancers; Complete resection of any type of carcinoma in situ, etc.);

7. Major organ surgery was performed or significant trauma was present within 4 weeks before the first administration of the study drug;

8. Weight loss 10% within 2 months before drug administration, or other indicators of severe malnutrition, or body mass index (BMI)<17.5 at the time of signing the informed consent.

9. The following conditions were present within 6 months prior to the first study dose:

myocardial infarction, severe/unstable angina, NYHA class 2 or higher cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, and symptomatic congestive heart failure , hypertensive crisis, or hypertensive encephalopathy; patients with known hypertension, coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction <50% must be treated with optimal stabilization as determined by the treating physician medical plan;

10. Pericardial effusion, pleural effusion or abdominal effusion with clinical symptoms, signs or requiring symptomatic treatment;

11. Poorly controlled pain related;

12. The presence of uncontrolled or symptomatic active central nervous system (CNS) metastases, which can be manifested by the onset of clinical symptoms, cerebral edema, spinal cord compression, carcinomatous meningitis, leptomeningeal disease, and/or progressive growth;

13. Active infection, including tuberculosis (clinical diagnosis including clinical history, physical examination and imaging findings, as well as TB tests according to local medical routine), hepatitis B, hepatitis C or human immunodeficiency virus (HIV antibody positive);

14. Pregnant or lactating women;

15. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;

16. Have serious psychological or mental abnormality, which affects the compliance of the subject to participate in this clinical study;

17. Idiopathic pulmonary fibrosis, drug-induced pneumonia, machine-induced pneumonia (bronchiolitis obliterans), radioactive pneumonia with clinical symptoms or requiring steroid treatment, active pneumonia, or other moderate to severe lung diseases that seriously affect lung function ;

18. History of autoimmune disease;

19. Persons who have an immunodeficient disease or the other chronic immunosuppressive therapy, or who have received systemic immunomodulatory drugs (including, but not limited to, interferon or IL-2) within 14 days before first dose or within the 5 half-life of the drug (depend on whichever is longer), or received systemic glucocorticoid therapy (10mg daily of prednisone or equivalent glucocorticoids) or other systemic immunosuppressive therapy within 14 days before first dose;

20. Received any live vaccine (e.g. influenza vaccine against infectious diseases, chickenpox vaccine, etc.) within 14 days before first dose;

21. Other conditions deemed inappropriate for study participation by the investigator.

Related Conditions & MeSH terms

• Advanced Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• JS107
JS107, i.v., q3w

Combination Product:
• JS107 combination with Toripalimab
JS107 i.v., q3w combine with Toripalimab

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Junshi Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD	Determine maximum tolerated dose (MTD, if possible)	Up to approximately 12 months from first patient in.
Primary	RP2D	Recommended phase II dose (RP2D) for JS107 monotherapy and combination therapy	Up to approximately 24 months from first patient in.
Secondary	Drug concentrations in plasma	Drug concentrations in individual subjects at different time points after dosing	Up to approximately 24 months from first patient in.
Secondary	Immunogenicity	Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples	Up to approximately 24 months from first patient in.
Secondary	ORR	Objective response rate (ORR) was assessed based on RECIST V1.1 criteria	Up to approximately 24 months from first patient in.